A US FDA complete response letter (CRL) for Allergan PLC's ulipristal acetate in the treatment of abnormal uterine bleeding in women with uterine fibroids removes an overhang on the company's effort to sell its women's health unit, but it will also negatively impact any potential valuation of the business.
Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection
US FDA issued a complete response letter for ulipristal acetate for the treatment of bleeding in women with uterine fibroids. The action wasn't unanticipated, but a disappointment nonetheless while Allergan tries to sell its women's health unit.
More from Immunological
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.
• By
The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.
• By
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.
More from Therapy Areas
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.